Infectious Disease Conf Aug 07, 12 - Journal Session from The Lancet

[Wanla]

Journal Session: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
 
Rotating resident: Pattaramon S.
Fellow: Sunee C.

Rm 117 Internal Medicine Bldg
09:00-10:00

For more, please visit www.idchula.org